Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) – Investment analysts at Capital One Financial boosted their Q3 2024 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a report released on Wednesday, October 16th. Capital One Financial analyst N. Quibria now anticipates that the biopharmaceutical company will post earnings per share of ($0.22) for the quarter, up from their prior forecast of ($0.25). The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Capital One Financial also issued estimates for Fennec Pharmaceuticals’ Q4 2024 earnings at ($0.18) EPS and FY2024 earnings at ($0.03) EPS.
Fennec Pharmaceuticals (TSE:FRX – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.08 by C($0.35). The business had revenue of C$9.94 million for the quarter, compared to the consensus estimate of C$18.67 million. Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%.
Fennec Pharmaceuticals Stock Performance
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Further Reading
- Five stocks we like better than Fennec Pharmaceuticals
- What is the Nasdaq? Complete Overview with History
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Overbought Stocks Explained: Should You Trade Them?
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Consumer Discretionary Stocks Explained
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.